Cover Image

DOD ‐ SSR : An Adaptive Seamless Phase II / III Design With Dose Optimization Decision and Sample Size Re‐estimation

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Meizi Liu, Jianchang Lin, Yefei Zhang, Rachael Liu
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Statistics in Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

BEAM: Bayesian Hybrid Design With Adaptive Sample Size Through Multisource Exchangeability Modeling
by: Feng Tian, et al.
Published: (2025)

A Flexible Seamless Phase 2/3 Design With Biomarker‐Driven Subgroup Enrichment and Sample Size Re‐Estimation
by: Zizhong Tian, et al.
Published: (2025)

Adaptive Seamless Phase II / III Randomization Test Considering Treatment Group Selection Based on Short–Term Binary Outcomes
by: Funato Sato, et al.
Published: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
by: Yichen Yan, et al.
Published: (2025)

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority
by: Hakim‐Moulay Dehbi, et al.
Published: (2025)

Sample Size Re‐Estimation in Blinded Hybrid‐Control Design Using Inverse Probability Weighting
by: Masahiro Kojima, et al.
Published: (2026)

Sample Size Calculation for the ROCI Design
by: Henry Bern, et al.
Published: (2026)

Statistical Inference for a Two‐Stage Adaptive Seamless Design Using Different Binary Endpoints
by: Ryota Ishii, et al.
Published: (2025)

Comments on “Sample Size Adaptation Designs and Efficiency Comparison With Group Sequential Designs”
by: Meinhard Kieser, et al.
Published: (2025)

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
by: Yingjie Qiu, et al.
Published: (2026)

Flexible Seamless 2-in-1 Design with Sample Size Adaptation
by: Li, Runjia, et al.
Published: (2022)

Improving the Effectiveness of Sample Size Re‐Estimation: An Operating Characteristic Focused, Hybrid Frequentist‐Bayesian Approach
by: Ping Gao
Published: (2025)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
by: Andrew Hall, et al.
Published: (2026)

A Seamless Design for the Combination of a Case–Control and a Cohort Diagnostic Accuracy Study
by: Eric Bibiza‐Freiwald, et al.
Published: (2025)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
by: Alessandra Serra, et al.
Published: (2025)

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility
by: Rebecca B. Silva, et al.
Published: (2024)

COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies
by: Kai Chen, et al.
Published: (2025)

Semiparametric Inference for a Two‐Phase Failure‐Time‐Auxiliary‐Dependent Sampling Design
by: Xu Cao, et al.
Published: (2025)

Bayesian Adaptive Enrichment Design for Continuous Biomarkers
by: Yue Tu, et al.
Published: (2025)

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
by: Chloe E. Falke, et al.
Published: (2025)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
by: Adrien Ollier, et al.
Published: (2025)

Confidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance
by: David S. Robertson, et al.
Published: (2025)

Sample Size Adjustment in Sequential Multiple Assignment Randomized Trials
by: Liwen Wu, et al.
Published: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Moka Komaki, et al.
Published: (2026)

Sample Size and Power Calculations With Win Measures Based on Hierarchical Endpoints
by: Huiman Barnhart, et al.
Published: (2025)

Regional Consistency Evaluation and Sample Size Calculation Under Two MRCTs
by: Kunhai Qing, et al.
Published: (2025)

Confidence Intervals and Sample Size for the ICC in Two‐Way ANOVA Models
by: Dipro Mondal, et al.
Published: (2025)

A Note on the Sample Size Formula for a Win Ratio Endpoint
by: Se Yoon Lee
Published: (2025)

Bioequivalence Design With Sampling Distribution Segments
by: Luke Hagar, et al.
Published: (2025)

Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology
by: Benjamin F. Hartley, et al.
Published: (2025)

Power and Sample Size Calculations for Cluster Randomized Hybrid Type 2 Effectiveness‐Implementation Studies
by: Melody A. Owen, et al.
Published: (2025)

Linear Mixed Modeling of Federated Data When Only the Mean, Covariance, and Sample Size Are Available
by: Marie Analiz April Limpoco, et al.
Published: (2024)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
by: Xinran Huang, et al.
Published: (2024)

Can the Unit Size Predict Outcomes? Testing for Informativeness in Three‐Level Designs
by: Samuel Anyaso‐Samuel, et al.
Published: (2025)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
by: Cheng‐Han Yang, et al.
Published: (2026)

Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization
by: Peng Yang, et al.
Published: (2024)

Bayesian Estimation of Hierarchical Linear Models From Incomplete Data: Cluster‐Level Interaction Effects and Small Sample Sizes
by: Dongho Shin, et al.
Published: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
by: Gi‐Ming Wang, et al.
Published: (2026)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
by: Holger Dette, et al.
Published: (2025)

Adaptive Designs in Trials With Time‐to‐Event Endpoints and Covariate Adjustment
by: Daniel Backenroth, et al.
Published: (2026)